phrykt

Altimmune, Inc. (ALT): who owns it and who trades it

As of Nov 16, 2026, ALT insiders reported 14 purchases worth $452K in the last 12 months. The largest buyer was Jerome Benedict Durso (Director), with $263K. 6 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Altimmune

From the latest filings

Overall: more buying than selling. Funds, insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ALT

210 funds and institutions reported ALT shares worth $463M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 15.7%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

BlackRock, Inc.15.7%
Deep Track Capital, LP14.8%
State Street Corp9.3%
TCG Crossover Management, LLC7.7%
Vanguard Capital Management LLC6.3%
Vanguard Portfolio Management LLC5.6%
Marshall Wace, LLP5.3%
Viking Global Investors LP5.2%
Ra Capital Management, L.P.5.0%
Geode Capital Management, LLC3.9%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.20.39M15.67%$62M+59%
Deep Track Capital, LP19.25M14.80%$58.5M–
State Street Corp12.10M9.30%$36.8M+69%
TCG Crossover Management, LLC10.00M7.69%$30.4M–
Vanguard Capital Management LLC8.18M6.29%$24.9M+45%
Vanguard Portfolio Management LLC7.33M5.64%$22.3M+36%
Marshall Wace, LLP6.84M5.26%$20.8M+70%
Viking Global Investors LP6.70M5.15%$20.4M–
Ra Capital Management, L.P.6.50M5.00%$19.8M–
Geode Capital Management, LLC5.01M3.85%$15.2M+61%
Woodline Partners LP3.40M2.61%$10.3M–
Millennium Management LLC3.31M2.54%$10.1M+2%
Nantahala Capital Management, LLC3.00M2.31%$9.1M–
Trails Edge Capital Partners, LP2.66M2.05%$8.1M–
Nuveen, LLC2.41M1.85%$7.3M+3%
Two Sigma Investments, LP2.38M1.83%$7.2M-4%
Goldman Sachs Group Inc2.21M1.70%$6.7M+64%
Great Point Partners LLC1.74M1.34%$5.3M–
Northern Trust Corp1.60M1.23%$4.9M+60%
Weiss Asset Management LP1.53M1.18%$4.7M–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ALT insiders reported $452K of open-market purchases and $0 of sales.

Purchases, 12 months
$452K
14 trades, 6 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Nov 13, 2026
Filed Nov 13, 2026

Purchases and sales by month

$110K$110KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 13, 2026Gregory L WeaverCFOPurchase10,000$1.62$16.2KForm 4
Nov 13, 2026Jerome Benedict DursoCEOPurchase30,700$1.62$49.7KForm 4
Nov 13, 2026Wayne PisanoDirectorPurchase10,000$1.64$16.4KForm 4
Aug 13, 2026Jerome Benedict DursoCEOPurchase15,000$2.95$44.2KForm 4
Apr 6, 2026John GillDirectorPurchase9,200$3.41$31.4KForm 4
Apr 1, 2026Gregory L WeaverCFOPurchase10,000$3.15$31.5KForm 4
Apr 1, 2026Jerome Benedict DursoCEOPurchase15,000$3.14$47.1KForm 4
Mar 6, 2026Gregory L WeaverCFOPurchase5,000$3.54$17.7KForm 4
Mar 6, 2026Jerome Benedict DursoCEOPurchase20,000$3.54$70.8KForm 4
Jan 8, 2026Wayne PisanoDirectorPurchase5,000$4.08$20.4KForm 4
Jan 5, 2026Catherine A. SohnDirectorPurchase500$4.24$2.1KForm 4
Dec 29, 2025Diane JorkaskyDirectorPurchase527$3.80$2KForm 4
Dec 23, 2025John GillDirectorPurchase12,500$4.10$51.2KForm 4
Dec 22, 2025Jerome Benedict DursoDirectorPurchase12,500$4.13$51.6KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Jerome Benedict DursoDirector$263K–Nov 13, 2026
John GillDirector$82.6K–Apr 6, 2026
Gregory L WeaverChief Financial Officer$65.4K–Nov 13, 2026
Wayne PisanoDirector$36.8K–Nov 13, 2026
Catherine A. SohnDirector$2.1K–Jan 5, 2026
Diane JorkaskyDirector$2K–Dec 29, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ALT short interest

Very high short interest. 21.7% of ALT shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went up 12%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 42.13M ALT shares were sold short, 21.7% of the shares outstanding, down 0.2% from the report before. At the average daily volume of 3.46M shares, buying them all back would take about 12.2 trading days (days to cover).

Shares short, % of all shares

21.7%May 15Oct 3042.7%

Days to cover

12.2May 15Oct 3016.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202642.13M21.66%-0%3.46M12.2
Oct 15, 202642.23M21.71%-8%4.05M10.4
Sep 30, 202646.08M23.69%-11%4.37M10.5
Sep 15, 202651.75M26.60%+4%3.37M15.4
Aug 31, 202649.71M25.56%-2%4.20M11.8
Aug 14, 202650.97M26.20%-2%4.62M11.0
Jul 31, 202651.94M39.93%+8%4.53M11.4
Jul 15, 202648.24M37.09%+1%3.85M12.5
Jun 30, 202647.63M36.62%+14%5.90M8.1
Jun 15, 202641.93M32.23%+7%2.88M14.6
May 29, 202639.12M30.08%+4%2.70M14.5
May 15, 202637.64M28.94%+6%3.42M11.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Altimmune company events

Altimmune filed 14 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Oct 29, 2026.

  1. Oct 29, 2026DebtTook on new debt. Filing
  2. Oct 27, 2026LeadershipThe Board of Directors, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Peter Greenleaf and Alex Howarth as directors of the Board effective November 2, 2026, and approved an increase in its size from nine to eleven directors. Filing
  3. Sep 29, 2026LeadershipThe Board of Directors of Altimmune, Inc. appointed Richard Menziuso as the Company’s Vice President, Global Controller and Principal Accounting Officer effective as of September 29, 2026. Filing
  4. Aug 12, 2026ResultsReleased financial results. Filing
  5. Jul 28, 2026AnnouncementAs noted above, on July 28, 2026, the Company announced the positive topline results from the RECLAIM Phase 2 trial evaluating the 2.4 mg dose of pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, in patients with moderate to severe AUD. The trial met its primary… Filing
  6. Jun 16, 2026AnnouncementAltimmune, Inc. announced plans to relocate its corporate headquarters from Gaithersburg, Maryland to Morristown, New Jersey later this year. Filing
  7. May 13, 2026ResultsReleased financial results. Filing
  8. Apr 24, 2026AgreementAltimmune, Inc. entered into an underwriting agreement with Leerink Partners LLC and Barclays Capital Inc., as representatives of the several underwriters named therein pursuant to which the Company agreed to issue and sell (i) 64,250,000 shares of the Company’s common stock, par value $0.0001 per… Filing
  9. Apr 16, 2026VoteReported shareholder vote results. Filing
  10. Mar 5, 2026ResultsReleased financial results. Filing
  11. Feb 3, 2026AnnouncementAltimmune, Inc. has established Thursday, April 16, 2026 as the date of the Company's 2026 Annual Meeting of Stockholders to align with the standard second quarter annual meeting calendar for companies operating on a 12/31 fiscal year-end. Filing
  12. Jan 28, 2026AgreementAltimmune, Inc. entered into a Securities Purchase Agreement with a new fundamental institutional investor relating to the issuance of 12,397,920 shares of the Company’s common stock, par value of $0.0001 per share and pre-funded warrants to purchase up to 4,647,534 shares of Common Stock (such… Filing
  13. Dec 19, 2025AnnouncementThe Company announced positive topline results from the IMPACT Phase 2b trial of pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, in patients with metabolic dysfunction-associated steatohepatitis at 48 weeks. Filing
  14. Dec 1, 2025LeadershipAltimmune, Inc. announced that, effective January 1, 2026, Vipin K. Garg, Ph.D. will transition from his role as President and Chief Executive Officer. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Altimmune financials

Famous investors that hold ALT

6 of the 50 well-known investors we track reported holding ALT in their latest 13F filing. The largest position is Andreas Halvorsen's, worth $19.2M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Andreas Halvorsen · Viking Global InvestorsQ3 20266.70M$19.2M0.1%No change
Israel Englander · Millennium ManagementQ3 20263.84M$11M0.0%+16%
Steve Cohen · Point72 Asset ManagementQ3 20261.46M$4.2M0.0%+200%
Ken Griffin · Citadel AdvisorsQ3 2026693,769$2M0.0%-29%
Jim Simons · Renaissance TechnologiesQ3 2026108,146$309K0.0%+51%
Jeremy Grantham · GMOQ3 202635,659$102K0.0%-57%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ALT in the last 120 days.

FiledHolderFormStake
Nov 16, 2026TCG Crossover GP II, LLC13G/A2.5%
Nov 16, 2026TCG Crossover GP II, LLC13G/A2.5%
Nov 10, 2026STATE STREET CORPORATION13G4.3%
Nov 10, 2026STATE STREET CORPORATION13G4.3%

Questions about Altimmune, Inc. (ALT) stock

Who owns the most ALT stock?

The largest reported owner of Altimmune, Inc. (ALT) is BlackRock, Inc., with 15.7% of the company. In total, 210 funds and institutions reported holding ALT at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are ALT insiders buying or selling?

In the last 12 months, ALT insiders reported 14 open-market purchases worth $452K and no sales. The latest trade was on Nov 13, 2026. See every trade.

What is the short interest in ALT?

As of Oct 30, 2026, 42.13M ALT shares were sold short, 21.7% of the shares outstanding, down 0.2% from the report before. At the average daily volume of 3.46M shares, buying them all back would take about 12.2 trading days (days to cover). See the history.

Which famous investors hold ALT?

6 of the 50 well-known investors we track reported ALT in their latest 13F filing, including Andreas Halvorsen, Israel Englander, Steve Cohen. The largest position is worth $19.2M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.